Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars
As The Firm Prepares For First Generic Rivals For Its Innovative Parkinson’s Drug Rytary
While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.
